Varicella-Zoster Virus Treatment & Management
- Author: Wayne E Anderson, DO; Chief Editor: Burke A Cunha, MD more...
Medical Care
- Treatment options are based on the patient's age, immune state, duration of symptoms, and presentation.
- Several studies indicate that antiviral medications decrease the duration of symptoms and the likelihood of postherpetic neuralgia, especially when initiated within 2 days of the onset of rash. In typical cases that involve individuals who are otherwise healthy, oral acyclovir may be prescribed. An important study by Kubeyinje (1997) suggested that the use of acyclovir in healthy young adults with zoster is not clearly justified, especially in situations of limited economic resources.[5]
- Acyclovir has 2 limitations—bioavailability and the existence of some resistant strains of varicella-zoster virus (VZV).
- Other medications, including valacyclovir, penciclovir, and famciclovir, are also available. They may have an increasing role in the treatment of typical zoster. Studies suggest that, when compared with oral acyclovir, the new medications may decrease the duration of the patient's pain.
- Dworkin et al (2009) conducted a randomized, placebo-controlled trial of oral oxycodone and oral gabapentin as potential treatments for acute pain in patients with herpes zoster. They found that controlled-release oxycodone was superior to placebo in the early period of pain (1-14 d). Gabapentin was not shown to yield a significantly greater relief of pain than placebo, although it conferred modest pain relief during the first week.[6]
Surgical Care
Surgical care may be required for complications of zoster, such as necrotizing fasciitis.
Consultations
- Consultation with a neurologist is indicated in cases of myelitis or encephalitis.
- Consultation with an infectious disease specialist may be helpful if bacterial superinfection or viral resistance to acyclovir is evident.
- Consultation with an ophthalmologist is indicated upon optic involvement.
- Consultation with a dermatologist may be helpful when the rash is atypical.
Furuta Y, Fukuda S, Suzuki S, et al. Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol. Jul 1997;52(3):316-9. [Medline].
Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis. Feb 1 2011;203(3):312-5. [Medline].
Pahud BA, Glaser CA, Dekker CL, Arvin AM, Schmid DS. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis. Feb 1 2011;203(3):316-23. [Medline].
Brink AA, van Gelder M, Wolffs PF, Bruggeman CA, van Loo IH. Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clin Infect Dis. Apr 15 2011;52(8):982-7. [Medline].
Kubeyinje EP. Cost-benefit of oral acyclovir in the treatment of herpes zoster. Int J Dermatol. Jun 1997;36(6):457-9. [Medline].
[Best Evidence] Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. Apr 2009;142(3):209-17. [Medline].
Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. Jul 2010;126(1):e1-8. [Medline].
Hviid A. Measles-mumps-rubella-varicella combination vaccine increases risk of febrile seizure. J Pediatr. Jan 2011;158(1):170. [Medline]. [Full Text].
[Guideline] Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. May 7 2010;59:1-12. [Medline]. [Full Text].
Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. Jan 12 2011;305(2):160-6. [Medline].
Schmader K, Levin M, Gnann J, McNeil S, Vesikari T, et al. Efficacy, immunogenicity, safety, and tolerability of zoster vaccine (ZV) in subjects 50 to 59 years of age (Poster/Abstract). Infectious Diseases Society of America. The 48th Annual Meeting of the Infectious Diseases Society of America. 10-21-2010;Vancouver, British Columbia, Canada:Ref Type: Abstract: 3363.
Pierson DL, Mehta SK, Gilden D, et al. Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization. J Infect Dis. Jun 1 2011;203(11):1542-5. [Medline]. [Full Text].
Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med. Jun 9 1997;157(11):1209-13. [Medline].
Rowbotham MC, Fields HL. The relationship of pain, allodynia and thermal sensation in post-herpetic neuralgia. Brain. Apr 1996;119 ( Pt 2):347-54. [Medline].
Oaklander AL, Romans K, Horasek S, et al. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol. Nov 1998;44(5):789-95. [Medline].
Baik JS, Kim WC, Heo JH, Zheng HY. Recurrent herpes zoster myelitis. J Korean Med Sci. Aug 1997;12(4):360-3. [Medline].
Carreau JP, Gola R, Cheynet F, Guyot L. [Zona of the cranial nerves. Current aspects]. Rev Stomatol Chir Maxillofac. Oct 1998;99(3):155-64. [Medline].
[Guideline] Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. Mar 14 2008;57(10):258-60. [Medline].
Cohen JI. Varicella-zoster virus. The virus. Infect Dis Clin North Am. Sep 1996;10(3):457-68. [Medline].
Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med. Jun 1 1999;130(11):922-32. [Medline].
Devinsky O, Cho ES, Petito CK, Price RW. Herpes zoster myelitis. Brain. Jun 1991;114 (Pt 3):1181-96. [Medline].
Fabian VA, Wood B, Crowley P, Kakulas BA. Herpes zoster brachial plexus neuritis. Clin Neuropathol. Mar-Apr 1997;16(2):61-4. [Medline].
Feder HM Jr, LaRussa P, Steinberg S, Gershon AA. Clinical varicella following varicella vaccination: don't be fooled. Pediatrics. Jun 1997;99(6):897-9. [Medline].
Gilden DH, Cohrs RJ, Mahalingam R. VZV vasculopathy and postherpetic neuralgia: progress and perspective on antiviral therapy. Neurology. Jan 11 2005;64(1):21-5. [Medline].
Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol. Sep 1997;36(9):667-72. [Medline].
Goldman GS. Universal varicella vaccination: efficacy trends and effect on herpes zoster. Int J Toxicol. Jul-Aug 2005;24(4):205-13. [Medline].
Hong JJ, Elgart ML. Gastrointestinal complications of dermatomal herpes zoster successfully treated with famciclovir and lactulose. J Am Acad Dermatol. Feb 1998;38(2 Pt 1):279-80. [Medline].
Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis. Sep 2007;9(3):237-40. [Medline].
Liang MG, Heidelberg KA, Jacobson RM, McEvoy MT. Herpes zoster after varicella immunization. J Am Acad Dermatol. May 1998;38(5 Pt 1):761-3. [Medline].
Mainka C, Fuss B, Geiger H, et al. Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol. Sep 1998;56(1):91-8. [Medline].
Morgan R, King D. Characteristics of patients with shingles admitted to a district general hospital. Postgrad Med J. Feb 1998;74(868):101-3. [Medline].
Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med. Jul 2007;74(7):489-94, 496, 498-9 passim. [Medline].
Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. Apr 1996;65(1):39-44. [Medline].
Sparks L, Russell C. The new varicella vaccine: efficacy, safety, and administration. J Pediatr Nurs. Apr 1998;13(2):85-94. [Medline].
Stein GE. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J Am Pharm Assoc (Wash). Mar-Apr 1997;NS37(2):157-63. [Medline].
Sugisaki K, Yoshida H. Varicella zoster virus meningoencephalitis accompanied by sporadic skin lesions in an older immunocompetent adult. J Infect Chemother. Aug 2007;13(4):270-2. [Medline].
Svozilkova P, Rihova E, Diblik P. Varicella zoster virus acute retinal necrosis following eye contusion: casereport. Virol J. Aug 31 2005;2:77. [Medline].
Vu AQ, Radonich MA, Heald PW. Herpes zoster in seven disparate dermatomes (zoster multiplex): report of a case and review of the literature. J Am Acad Dermatol. May 1999;40(5 Pt 2):868-9. [Medline].
Westenend PJ, Hoppenbrouwers WJ. [Fatal varicella-zoster encephalitis; a rare complication of herpes zoster]. Ned Tijdschr Geneeskd. Mar 21 1998;142(12):654-7. [Medline].

